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Abstract
Pulmonary arterial compliance (PAC), invasively assessed by the ratio of stroke volume to pulmonary arterial (PA) pulse pressure,
is a sensitive marker of right ventricular (RV)-PA coupling that differs across the spectrum of pulmonary hypertension (PH) and is
predictive of outcomes. We assessed whether the echocardiographically derived ratio of RV outflow tract velocity time integral to
PA systolic pressure (RVOT-VTI/PASP) (a) correlates with invasive PAC, (b) discriminates heart failure with preserved ejection-
associated PH (HFpEF-PH) from pulmonary arterial hypertension (PAH), and (c) is associated with functional capacity. We per-
formed a retrospective cohort study of patients with PAH (n¼ 70) and HFpEF-PH (n¼ 86), which was further dichotomized by
diastolic pressure gradient (DPG) into isolated post-capillary PH (DPG< 7mmHg; Ipc-PH, n¼ 54), and combined post- and pre-
capillary PH (DPG 7mm Hg; Cpc-PH, n¼ 32). Of the 156 patients, 146 had measurable RVOT-VTI or PASP and were included in
further analysis. RVOT-VTI/PASP correlated with invasive PAC overall (q¼ 0.61, P< 0.001) and for the PAH (q¼ 0.38, P¼ 0.002)
and HFpEF-PH (q¼ 0.63, P< 0.001) groups individually. RVOT-VTI/PASP differed significantly across the PH spectrum (PAH: 0.13
[0.010–0.25] vs. Cpc-PH: 0.20 [0.12–0.25] vs. Ipc-PH: 0.35 [0.22–0.44]; P< 0.001), distinguished HFpEF-PH from PAH
(AUC¼ 0.72, 95% CI¼ 0.63–0.81) and Cpc-PH from Ipc-PH (AUC¼ 0.78, 95% CI¼ 0.68–0.88), and remained independently
predictive of 6-min walk distance after multivariate analysis (standardized -coefficient¼ 27.7, 95% CI¼ 9.2–46.3; P¼ 0.004).
Echocardiographic RVOT-VTI/PASP is a novel non-invasive metric of PAC that differs across the spectrum of PH. It distinguishes
the degree of pre-capillary disease within HFpEF-PH and is predictive of functional capacity.
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Introduction
Pulmonary hypertension (PH) is deﬁned by a mean pulmon-
ary artery pressure (mPAP)  25mmHg by right heart cath-
eterization (RHC) and stems from a wide range of
etiologies.1 While PH associated with left heart disease
(LHD-PH) is common, pulmonary arterial hypertension
(PAH) remains a rare and progressive condition associated
with a high morbidity and mortality and warrants speciﬁc
therapeutics.2 Thus, distinguishing those patients with
intrinsic abnormalities of the pulmonary vasculature is clin-
ically relevant.
With increasing identiﬁcation and expanded hemo-
dynamic insight into PH, there has also been an increased
awareness of those patients with LHD-PH who also have
abnormalities of their pulmonary arterial vasculature, so-
called combined post- and pre-capillary disease (Cpc-PH),
as compared to those with isolated post-capillary PH (Ipc-
PH).1–3 Importantly, Cpc-PH may share features similar to
PAH including mortality, histopathologic, genetic, and
pathophysiologic mechanisms compared to Ipc-PH.4–8
Pulmonary arterial compliance (PAC), estimated as the
ratio of right ventricular (RV) stroke volume to pulmonary
arterial (PA) pulse pressure (PP), represents pulsatile RV
afterload.9 A reduction in PAC, representing increased PA
stiﬀness, is associated with increased reﬂected waves during
systole, increased PAPP, and increased RV pulsatile load.
Studies suggest PAC may be altered earlier in the course of
disease compared to pulmonary vascular resistant (PVR).10
PAC is of signiﬁcant prognostic value in both PAH and
LHD-PH and improves with PH therapy.9–13 PAC has
also been shown to eﬀectively discriminate Ipc-PH, Cpc-
PH, and PAH.4
Given the high prevalence of LHD-PH, and speciﬁcally
heart failure with preserved ejection fraction-associated PH
(HFpEF-PH), and the importance in diﬀerentiating it from
PAH, identifying readily available markers to help distin-
guish patients that require more invasive investigation is
important clinically.14–17 In this study, we propose the
ratio of RV outﬂow tract velocity time integral (RVOT-
VTI), a surrogate of RV SV, and pulmonary artery systolic
pressure (PASP; RVOT-VTI/PASP), as a simple, non-inva-
sive estimate of PAC and assess its ability to identify
patients across the spectrum of PH. We also sought to
assess its association with 6-min walk distance (6MWD) as
a marker of RV-PA uncoupling across the spectrum of PH.
Methods
Study population
We performed a retrospective cohort study of consecutive
patients referred to the Hospital of the University of
Pennsylvania and evaluated in the Pulmonary Hypertension
Program who underwent RHC and echocardiography within
one year, met criteria for PH deﬁned as mPAP  25mmHg,
and had a preserved left ventricular ejection fraction (LVEF)
on echocardiography. Patients were then stratiﬁed into PAH
or heart failure with preserved ejection fraction (HFpEF)-
associated PH (HFpEF-PH), as deﬁned by current guide-
lines,1,18 with HFpEF deﬁned by elevated pulmonary artery
wedge pressure (PAWP) > 15mmHg. HFpEF-PH was fur-
ther subdivided into Cpc-PH and Ipc-PH and deﬁned as PH
with a PAWP of > 15mmHg and diastolic pressure gradient
(DPG)  7mmHg and/or PVR > 3WU, or DPG< 7mmHg
and/or PVR 3WU, respectively1 (Suppl. Fig. 1). Patients
were excluded if they had a reduced LVEF or other known
causes of PH including World Health Organization (WHO)
groups III–V or congenital heart disease-associated PH.
Speciﬁcally, patients with signiﬁcant lung disease per review
of pulmonary function tests or chest computed tomography
were excluded, as described previously.19,20 Baseline demo-
graphic and clinical variables, including age, sex, body mass
index (BMI), cause of PAH (classiﬁed as idiopathic, connect-
ive tissue disease, or other), WHO functional class (FC), and
6MWD, were collected, as previously described.19 The study
was approved by the institutional review board of the
University of Pennsylvania (Protocol no. 820414).
Echo-Doppler exam
All patients underwent a clinically indicated echo-Doppler
exam using the Philips Sonos 7500, IE33 (Philips Medical
Systems, Andover, MA, USA) or GE Vivid 7 Ultrasound
(GE, Milwaukee, WI, USA) systems. All studies were ana-
lyzed using ProSolv CardioVascular Client software
(Fujiﬁlm Medical Systems, Stamford, CT, USA). The echo-
cardiograms were analyzed by two independent PH cardi-
ologists (JAM, AV) in accordance with the American
Society of Echocardiography (ASE) guidelines, and blinded
to patient clinical characteristics, invasive hemodynamics, or
outcomes, as previously described.19 The echo-Doppler
exam included standard assessments of right- and left-
sided heart chambers and vasculature. Speciﬁcally, this
included right atrial (RA) size and planimetered RA area1
at end-systole (in the apical four-chamber view), right
(RVIDd) and left (LVIDd) ventricular dimensions (obtained
at end-diastole in the apical four-chamber view), RV end-
diastolic area (RVAd) and RV end-systolic area (RVAs),
with right ventricular fractional area of change (RV FAC)
calculated in the standard manner ([RVAd- RVAs]/
RVAd 100). Tricuspid annular plane systolic excursion
(TAPSE) was measured either from the M-mode at the lat-
eral tricuspid annulus oﬀ the apical four-chamber view, or
from the two-dimensional (2D) apical four-chamber view.
Speciﬁcally, if an M-mode TAPSE was not available or of
adequate quality, the 2D apical four-chamber view was
used, with TAPSE measured by subtracting the distance of
displacement of the lateral tricuspid annulus between end-
systole and end-diastole, a technique that has been shown to
tightly correlate with M-mode TAPSE, as previously
described.19,21,22 Both RA area and RV end-diastolic area
were indexed to patient height. RVOT VTI (3-beat average),
2 | Noninvasive PA compliance and PH phenotype Bhattacharya et al.
acceleration time (AccT), and systolic notching pattern were
obtained from the RVOT pulse wave Doppler proﬁle in the
parasternal short- or long-axis views. The maximal trans-
tricuspid ﬂow velocity was obtained in the usual manner
and PASP was calculated using the sum of the modiﬁed
Bernoulli equation (4v2) and estimated RA pressure as rec-
ommended by ASE guidelines.23 Diastolic function was
assessed by trans-mitral Doppler velocity and tissue
Doppler using standard techniques.8
Invasive hemodynamics
All patients underwent standard clinical hemodynamic assess-
ment by RHC with all tracings reviewed and values reported
at end-expiration, as previously described. Indirect Fick (with
an assumed O2 consumption of 125mL/min/m2BSA) was
used to estimate cardiac output.1
Statistical analysis
Categorical variables are reported as n (%) and continuous
variables are reported with mean standard deviation (SD)
or median (interquartile range [IQR]) for normally and non-
normally distributed variables, respectively. Univariate dif-
ferences between PH phenotypes, namely Ipc-PH, Cpc-PH,
and PAH, were assessed using t-tests/ANOVA or Wilcoxon
rank-sum (Mann–Whitney U) test/Kruskal–Wallis test for
normally/non-normally distributed data, respectively. Using
Kruskal–Wallis tests, we particularly assessed the diﬀerences
in non-invasively estimated PAC as measured by RVOT-
VTI/PASP, between the three groups, along with other
echocardiographic and invasive hemodynamic variables.
To determine reproducibility of RVOT-VTI, intra-class cor-
relation coeﬃcient (ICC) was calculated to measure variabil-
ity and agreement between independent PH cardiologists.
Spearman correlation coeﬃcient was used to determine the
correlation between invasively measured PAC to the non-
invasively measured RVOT-VTI/PASP. ROC analysis was
performed to assess the discriminative ability of RVOT-
VTI/PASP as a predictive tool to diﬀerentiate between PH
subgroups, with the Youden index used to determine the
optimal cut-oﬀ point to diﬀerentiate HFpEF-PH phenotypes.
Univariate linear regression was used to determine predictors
of functional capacity as measured by 6MWD. Variables with a
P value < 0.25 on univariate analysis were entered into a multi-
variate linear regression model to examine the association
between 6MWD and RVOT-VTI/PASP. All analyses were
performed in Stata 14.2 (StataCorp, 2017, College Station,
TX, USA). A P value< 0.05 was considered signiﬁcant.
Results
Baseline characteristics
A total of 156 patients comprised the total cohort with 86
having HFpEF-PH and 70 with PAH (idiopathic: n¼ 36
[51.4%], connective tissue disease: n¼ 23 [32.9%], other:
n¼ 11 [15.7%]). Of the 156 total patients, 146 had measur-
able RVOT-VTI and PASP and were included in further
analysis (Suppl. Fig. 1). Median time between echocardio-
gram and RHC was 22.5 days (IQR¼ 6–43). As noted in
Table 1 and Suppl. Tables 1 and 2, there was a signiﬁcant
diﬀerence in age (P< 0.001), without diﬀerences in sex,
BMI, or 6MWD across PH subgroups.
Echocardiographic data
Echo-Doppler data revealed similarities in LVEF across
groups, but with diﬀerences in parameters of left heart struc-
ture, including IVS and LVIDd, which were more promin-
ent in the HFpEF-PH subgroups compared to the PAH
group (Table 1, Suppl. Table 1). Furthermore, several mar-
kers of RV dysfunction and disrupted RV-PA interaction
were more pronounced in moving across the PH subgroups
(Ipc-PH, Cpc-PH, and PAH). For example, RV:LV ratio
and presence of a notched RVOT pulsed-wave Doppler pro-
ﬁle increased across groups along with reductions in AccT,
RVOT-VTI, and TAPSE. Additionally, RV fractional area
change was lower in PAH patients compared to HFpEF-PH
patients (31% vs. 24%, P< 0.001; Suppl. Table 1). Similar
ﬁndings were seen comparing the Ipc-PH and Cpc-PH
groups (Suppl. Table 2). Finally, ICC between readers
for RVOT-VTI was 0.97 (95% conﬁdence interval [CI]¼
0.96–0.98) and 0.98 (95% CI¼ 0.97–0.99) for PASP.
Invasive hemodynamics
Invasive hemodynamic data revealed signiﬁcant diﬀerences
across groups including increased mPAP, TPG, DPG, and
PVR with a reduction in CO and PAC in in PAH compared
to the other groups (Table 1 and Suppl. Tables 1 and 2).
Of note, RAP was signiﬁcantly lower in PAH compared to
HFpEF-PH subgroups, with PAWP similarly and signiﬁ-
cantly increased in the HFpEF-PH subgroups compared
to PAH (Suppl. Tables 1 and 2).
Non-invasive assessment of PAC
As seen in Fig. 1, RVOT-VTI/PASP correlated with inva-
sively measured PAC for the group overall (q¼ 0.61,
P< 0.001) and remained signiﬁcantly correlated for the
PAH (q¼ 0.38, P¼ 0.002) and HFpEF-PH (q¼ 0.63,
P< 0.001) groups individually. Furthermore, non-invasive
PAC as determined by RVOT-VTI/PASP was signiﬁcantly
lower in the PAH group (median¼ 0.13, IQR¼ 0.010–0.25)
compared to the HFpEF-PH group (median¼ 0.25, IQR¼
0.16–0.39; P< 0.001; Suppl. Table 1 and Fig. 2a) and diﬀered
across the spectrum of PH with the lowest ratio in those with
PAH, intermediate in Cpc-PH, and the highest in those with
Ipc-PH (P< 0.001; Table 1 and Fig. 2b).
In an eﬀort to reproduce the invasively derived PAC-
PVR product (the ‘RC’ time), as previously described,4,13
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and assess if RVOT-VTI/PASP would maintain that rela-
tionship, we plotted RVOT-VTI/PASP versus PVR as seen
in Figs. 3 and 4. As noted in these ﬁgures, for a given PVR,
the PAC in the Ipc-PH group, whether assessed invasively or
non-invasively using RVOT-VTI/PASP, was shifted down-
ward and to the left compared to the Cpc-PH and PAH
groups. There was a signiﬁcant diﬀerence in the RVOT-
VTI/PASP to PVR product across groups with Ipc-PH
displaying the lowest and most leftward-shifted (med-
ian¼ 0.039, IQR¼ 0.027–0.059), followed by Cpc-PH (med-
ian¼ 0.053, IQR¼ 0.040–0.088) with the PAH group the
highest and shifted most rightward (median¼ 0.088,
IQR¼ 0.059–0.139; P< 0.001). Speciﬁcally, this relationship
is signiﬁcantly diﬀerent within HFpEF-PH (Ipc-PH vs.
Cpc-PH: P¼ 0.009). ROC analysis revealed modest ability
of RVOT-VTI/PASP to diﬀerentiate HFpEF-PH from
PAH groups (area under the curve [AUC]¼ 0.72, 95%
CI¼ 0.63–0.81) and Ipc-PH from Cpc-PH (AUC¼ 0.78,
95% CI¼ 0.68–0.88), at a Youden index cut-oﬀ point of
0.27 (AUC¼ 0.73; sensitivity¼ 62%, speciﬁcity¼ 84%) to
distinguish Ipc-PH from Cpc-PH, with a similar perform-
ance to invasively measured PAC (Fig. 5).
RVOT-VTI/PASP and 6MWD
We also assessed predictors of functional capacity as
assessed by 6MWD in using linear regression analysis.
RVOT-VTI/PASP was an independent predictor of
Table 1. Demographic, clinical, echocardiographic, and hemodynamic characteristics across PH subgroups.
Ipc-PH
DPG< 7mmHg (n¼ 54)
Cpc-PH
DPG 7mmHg (n¼ 32) PAH (n¼ 70) P value
Baseline characteristics
Mean age (years) 65.3 13 66.7 14 54.9 15 < 0.001
Male (n (%)) 20 (37) 12 (38) 15 (21) 0.24
Race (n (% White)) 35 (65) 25 (78) 49 (70) 0.78
BMI (kg/m2) 30.5 (25–38) 29.2 (26–36) 28 (24–33) 0.12
6MWD (m) 278 114 225 117 284 117 0.42
Echocardiographic variables
LVEF (%) 64 7.7 66 10.5 66 11.3 0.36
IVS (cm) 1.2 (1.1–1.5) 1.2 (1–1.4) 1 (0.9–1.2) < 0.001
LVIDd (cm) 4.72 0.64 4.4 0.97 3.8 0.57 0.001
LA d (cm) 4.7 0.78 4.7 0.82 3.4 0.61 0.09
PASP (est TTE) (mmHg) 53.0 20.7 72.2 24 72.7 28.8 < 0.001
TR grade 3 (n (%)) 11 (20.4) 13 (40.6) 19 (27) 0.29
RV:LV ratio 0.97 0.25 1 0.23 1.3 0.35 0.004
RV FAC (%) 31.3 (27–41) 33.5 (24–38) 24.4 (16–30) < 0.001
RVOT-VTI (cm) 16.5 5 12.7 4 11 3 0.003
RVOT-VTI/PASP 0.35 (0.22–0.44) 0.20 (0.12–0.25) 0.13 (0.10–0.25) < 0.001
Acceleration time (ms) 99 29 77.5 17.8 69 18 < 0.001
TAPSE (mm) 17 (15–23) 15 (11–19) 16 (13–19) < 0.001
Notch (n (%)) 29 (54) 24 (75) 66 (96) 0.0003
Invasive hemodynamics
Heart rate (bpm) 69.5 12.8 77 10.9 82.2 15.7 0.05
Mean right atrial pressure (mmHg) 13 (11–17) 16 (12–21) 9 (6–14) < 0.001
PASP (mmHg) 63.35 16.6 80.22 19.2 86.53 21.1 0.193
PADP (mmHg) 24.65 4.8 34.88 5.9 34.27 8.2 < 0.001
mPAP (mmHg) 37.55 7.7 49.99 9.2 52.62 12.1 0.002
PCWP (mmHg) 23 (20–27) 22 (19.5–24) 10.5 (8–13) < 0.001
TPG (mmHg) 14.3 5.6 27.7 8.5 42.0 12 < 0.001
DPG (mmHg) 1.4 2.7 12.6 5 23.7 8 < 0.001
CO (L/min) 6.2 (4.7–7.9) 4.9 (3.7–6) 4.1 (3.3–4.7) < 0.001
CI (L/min/m2) 3.1 (2.6–3.8) 2.5 (2–2.8) 2.2 (1.9–2.6) < 0.001
PVR (WU) 2.2 (1.7–3) 6.2 (3.6–7.8) 11 (6.7–14.5) < 0.001
PAC (L/mmHg) 2.66 (1.7–3.4) 1.35 (0.97–2.15) 0.95 (0.64–1.41) < 0.001
SVR (WU) 14 (10.3–17) 16 (12.7–21.3) 17 (14–20) < 0.001
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6MWD on multivariate analysis after adjustment for age
and BMI (Table 2).
Discussion
Invasively derived PAC has emerged as an increasingly
important marker of RV pulsatile load and RV-PA uncou-
pling and is prognostically important across the spectrum of
PH.4,9 In addition, abnormalities in PAC may occur earlier
compared to PVR and thus may be a more sensitive marker
of PH disease severity. This study is the ﬁrst to describe
RVOT-VTI/PASP as a simpliﬁed, non-invasively derived
estimation of PAC. This study highlights the diﬀerences in
echocardiographic and hemodynamic parameters, including
signiﬁcant diﬀerences in RVOT-VTI/PASP, across the
spectrum of PH. We show for the ﬁrst time the ability of
RVOT-VTI/PASP to distinguish PAH from HFpEF-PH as
well as between Ipc-PH and Cpc-PH. Lastly, RVOT-VTI/
PASP remains an independent predictor of functional
capacity as assessed by 6MWD after multivariate analysis.
Previously, Mahapatra et al. reported on an echo-
Doppler estimate of PAC, calculated as echo-derived SV/
PAPP, and showed its prognostic value in patients with
PAH.24 Unfortunately, this approach is more time-intensive
and requires several mathematical assumptions to echocar-
diographically estimate SV and PAPP, while some param-
eters may not be available or interpretable in some
patients.25 The currently proposed metric serves to simplify
the estimate by Mahapatra et al. and allow for routine clin-
ical use.
Guazzi et al.26 as well as others have more recently
reported on the use of TAPSE/PASP as a surrogate of
Fig. 1. Correlation of RVOT-VTI/PASP to invasive PAC.
Fig. 2. Box plots of RVOT-VTI/PASP across PH subgroup. (a) HFpEF-PH vs. PAH. (b) Ipc-PH vs. Cpc-PH vs. PAH.
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PAC in several heart failure populations with strong correl-
ations with invasively measured PAC, speciﬁc markers
on cardiopulmonary exercise testing (CPET), and out-
comes.3,27–29 Interestingly, TAPSE/ PASP was not sensitive
for distinguishing Ipc-PH in a most recent analysis of
HFpEF-PH.26 Limitations of TAPSE including load
dependence, a reduction in TAPSE in the setting of atrial
ﬁbrillation independent of PH,21,30 as well as disruption of
longitudinal ﬁbers (and thus ‘‘falsely’’ reduced RV function
by TAPSE) after cardiac surgery31 may suggest RVOT-VTI/
PASP is more reﬂective of RV-PA uncoupling as it incorp-
orates a surrogate of RV stroke volume relative to a given
pressure. Furthermore, the RVOT-VTI, as a stroke volume
surrogate, incorporates full RV ejection (RV basal and free
Fig. 4. Dual scatter plot with invasive PAC (on left y-axis) and RVOT-VTI/PASP on right y-axis plotted against invasive PVR.
Fig. 3. Relationship of non-invasive compliance (RVOT-VTI/PASP) and invasively measured pulmonary vascular resistance (PVR) across PH
subgroups. Median RC Time: Ipc-PH: 0.039 (IQR¼ 0.027–0.059) vs. Cpc-PH: 0.053 (IQR¼ 0.040–0.088) vs. PAH: 0.088 (IQR¼ 0.059–0.139);
P< 0.001.
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wall motion) as opposed to TAPSE which reﬂects RV basal
motion only. In fact, in our study, while RVOT-VTI/PASP
independently predicted functional capacity as determined
by 6MWD, TAPSE/PASP did not.
RVOT-VTI/PASP in distinguishing PH subgroups
Identifying those with combined post- and pre-capillary PH,
termed Cpc-PH, and distinguishing them from PAH has
potential clinical and prognostic implications. We and
others have proposed use of echo-Doppler parameters in
stratifying these populations which can then more appropri-
ately identify patients who should proceed with invasive
assessment, trial of PH therapies, and/or enrollment in
clinical trials.7,15,16,32 As reported in this study, RVOT-VTI/
PASP displays discriminatory ability of PAH from HFpEF-
PH and perhaps more importantly within HFpEF-PH in dis-
tinguishing Cpc-PH and Ipc-PH. Importantly, and in contra-
distinction to our prior work including RVOT PW Doppler
notching and the ‘‘echo score,’’ this parameter serves as a
non-invasive surrogate of an invasively derived hemodynamic
metric, namely, PAC. Indeed, both notching alone and the
echo score (which includes the presence of RVOT notching
and/or acceleration time< 80ms) address the issue of hemo-
dynamic phenotyping, but do not speciﬁcally give a hemo-
dynamic value that can be integrated into understanding a
given patient’s hemodynamic condition. Moreover, notching
is a categorical variable that can sometimes be challenging to
Fig. 5. Receiver operating characteristic curves for RVOT-VTI/PASP to distinguish: (a) HFpEF-PH and PAH; and (b) Ipc-PH and Cpc-PH.
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correctly deﬁne, especially in non-expert hands, while the
tracing of a VTI and TR velocity may be less challenging.
Unlike the echo score or notching, the RVOT-VTI/PASP is a
continuous value and may serve as a non-invasive metric
gauging response to PH therapy in patients with PAH.33
Lastly, the echo score, while comprehensive, is a bit more
cumbersome to generate and integrates left-sided parameters
that do not speciﬁcally speak to RV-PA interaction. In sum-
mary, this metric does not negate the role of either notching
alone or the echo score but serves as another tool in the
non-invasive tool box for clinicians to phenotype patients.
Recently, studies have assessed the ability of the resis-
tance-compliance (RC) time, deﬁned as the product of inva-
sively derived PVR and PAC thereby integrating mean and
pulsatile components of RV afterload, to diﬀerentiate Cpc-
PH from Ipc-PH.4 Assad et al.4 and Gerges et al.3 have
showed that the RC time in Cpc-PH is elevated in a similar
fashion to that of PAH as compared to Ipc-PH, despite
similar PAWP elevations in both Cpc-PH and Ipc-PH.4
In the study by Assad et al., PAC was highest in Ipc-PH,
intermediate in Cpc-PH, and most reduced in PAH, consist-
ent with the presumed increase in PA stiﬀness across these
subgroups.4 Within this context, we have reproduced the
relationship between invasively determined PAC and PVR
which is altered in patients with Ipc-PH compared to
Cpc-PH and PAH using RVOT-VTI/PASP as the non-
invasive estimate of PAC.
Limitations
This study is limited by its modest sample size and single-
center design, which limited more robust multivariable
assessment as well as the generalizability of our ﬁndings to
other PH cohorts. Speciﬁcally, the prevalence of PAH,
Cpc-PH, and distribution compared to Ipc-PH may diﬀer
in other centers. In addition, recently, and well after the
conclusion of this analysis, changes to the deﬁnition of PH
overall (mPAP  20mmHg) and Cpc-PH (deﬁned by PVR
 3WU as opposed to DPG), have been proposed.34
The trend of RVOT-VTI/PASP persisted across the three
subgroups (Ipc-PH, Cpc-PH, and PAH) using the new
PVR deﬁnition (Cpc-PH deﬁned by PVR  3WU and Ipc-
PH< 3WU) with similar ﬁndings (P< 0.001). Furthermore,
while the RVOT PW Doppler proﬁle is a standard assess-
ment in our echocardiographic laboratory, it may not be
routinely interpreted in clinical echocardiography labora-
tories. While this is true, there are now signiﬁcant data
showing the importance of this proﬁle in the interpretation
and prognostication of PH and pulmonary vascular dis-
ease,17,35 and it is a recommended view in the latest PH
guidelines.1 Additionally, while echocardiographic variables
may not always be present/measurable, thus limiting gener-
alizability across populations, we were able to measure
RVOT-VTI/PASP in 146/156 (94%) of the overall study
cohort. Similarly, as mentioned above, this parameter is a
non-invasive surrogate of PAC and not a non-invasive cal-
culation of PAC. While this may in part explain modest
correlation with invasive PAC, its simplicity allows for
ease of calculation, with less measurement assumptions
and error, as well as limitation of views needed for its assess-
ment. Importantly, while there was an allowance for a
time period of up to one year between echocardiogram
and invasive hemodynamics, the majority of patients
had an echocardiogram and RHC within 30 days, which
represents clinical practice and thus suggests ‘‘real-world’’
applicability of this parameter. Lastly, 6MWD was the out-
come used to assess functional capacity in this study; while
there are known limitations to this metric,36 it is routinely
assessed in clinical practice and is a clinically available
parameter of submaximal functional capacity.
Conclusion
This study describes RVOT-VTI/PASP as a non-invasive
estimate of PAC, which distinguishes between PAH and
HFpEF-PH as well as within HFpEF-PH and is independ-
ently predictive of functional capacity as assessed by
6MWD. Further study is needed to validate this metric in
larger populations along with the assessment of its prognos-
tic ability, correlation with parameters on CPET, and its
change in response to PH therapy.
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